In this video, Francesco Lanza, MD, Romagna Transplant Network, Ravenna, Italy, shares some insights into the treatment landscape of acute myeloid leukemia (AML) and how this has changed over the years with the introduction of novel targeted agents. Prof. Lanza first highlights the role of stem cell transplantation in this disease, and then explains the growing role of novel and personalized therapies. Following this, Prof. Lanza discusses how next-generation sequencing (NGS) techniques have allowed for a better understanding of disease biology, and concludes by commenting on how IDH-1/2 inhibitors and FLT3 inhibitors have provided valuable treatment options for patients with various subcategories of AML. This interview took place at the 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.